Bispecific T-cell engager therapy for multiple myeloma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Current multiple myeloma (MM) treatments, including triplet/quadruplet regimens and autologous stem cell transplant (ASCT), achieve deep responses but relapse is common.
• Drug resistance at first relapse presents a significant therapeutic challenge in MM management.
• T-cell engager (TCE) therapies have emerged as a promising immunotherapy option for heavily pretreated MM patients.

Purpose of the Study:

• To review the design and clinical application of T-cell engager (TCE) therapies in multiple myeloma (MM).
• To discuss how TCEs address the therapeutic gap in relapsed or refractory MM.
• To explore the potential of combination approaches and earlier TCE utilization for enhanced treatment outcomes.

Main Methods:

• Review of clinical data and literature on T-cell engager therapies in multiple myeloma.
• Analysis of bispecific TCEs (teclistamab, elranatamab, talquetamab) approved by the FDA.
• Discussion of treatment strategies including combination therapy and outpatient step-up dosing (SUD).

Main Results:

• TCE therapies demonstrate remarkable response rates and prolonged remissions in heavily pretreated MM patients.
• Three bispecific TCEs (teclistamab, elranatamab, talquetamab) have received FDA approval.
• Combination strategies and earlier initiation of TCEs show potential for overcoming resistance and improving response depth/durability.

Conclusions:

• T-cell engager therapies represent a significant advancement in treating relapsed/refractory multiple myeloma.
• Optimizing TCE use through combinations and earlier administration may enhance patient outcomes.
• Outpatient step-up dosing (SUD) facilitates wider adoption of TCEs in community settings.